Dalpiciclib for hormone receptor–positive advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older, and you’re able to meet the trial’s hormone-status rules (postmenopausal, or pre/peri-menopausal with a hormone-blocking shot during the study).
- Your breast cancer tests positive for hormone receptors, and it has focal recurrence or metastasis that can’t be treated with curative surgery or radiation.
- Your overall health allows treatment (ECOG performance status 0 to 2).
- If you can become pregnant: you must have a negative pregnancy test within 28 days and use highly effective birth control during the study and for 1 year after the last dose; you must not be pregnant or breastfeeding.
- You may not be in another treatment trial at the same time, and you must be willing to follow study visits, labs, and treatment plan.
- You must not have major uncontrolled illnesses (like uncontrolled blood pressure, serious active infection such as hepatitis B/C or HIV, or significant liver/kidney problems), and you must not have had serious side effects (CTCAE grade 3 or higher) from prior treatment that haven’t improved yet.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three drugs (dalpiciclib, entinostat, and letrozole) for women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. It aims to see if adding these medications before surgery can help shrink the tumor.
This trial tests whether adding the drug dalpiciclib to standard hormone therapy improves outcomes for people with a certain type of early breast cancer (hormone receptor-positive, HER2-negative). It may help lower the risk of the cancer coming back.
This trial tests a combination of two drugs, dalpiciclib and letrozole, as maintenance therapy after first-line chemotherapy for HR-positive, HER2-negative metastatic breast cancer. The goal is to see if this combination helps keep the cancer from growing.
This study tests a new combination of two medications given before surgery for stage II-III hormone-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes, possibly making surgery more successful.
This trial tests a combination of radiation to the brain, a hormone therapy, and a targeted drug called dalpiciclib for people with advanced breast cancer that has spread to the brain. The goal is to see if this combination can help control the cancer in the brain and elsewhere.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.